Phentermine Prescribed Online: The DEA Telehealth Rule Before 2027
Right now, yes: through December 31, 2026, a DEA-registered prescriber can prescribe phentermine or Qsymia by telemedicine without ever seeing you in person, under a temporary DEA and HHS rule. Both are Schedule IV controlled substances, so that permission depends on federal telemedicine flexibilities that expire at the end of 2026 unless DEA replaces or extends them. GLP-1 medications such as semaglutide and tirzepatide are not controlled substances, so this deadline does not affect them.
Key takeaways
- Phentermine (Adipex-P, Lomaira) and Qsymia are Schedule IV; Contrave and the GLP-1s are not on DEA's controlled substance list.
- The fourth temporary extension of COVID-era telemedicine flexibilities runs from January 1 through December 31, 2026.
- DEA sent a final telemedicine "special registration" rule to the White House Office of Information and Regulatory Affairs on August 25, 2026; as of a September 2026 law-firm alert, its text was not public.
- If the flexibilities lapse without a replacement, the Ryan Haight Act default requires at least one in-person evaluation before a practitioner prescribes controlled substances remotely.
- States add their own rules, including prescription monitoring database checks and weight-loss thresholds for continuing phentermine.
Why phentermine is treated differently from GLP-1s
The difference is controlled-substance scheduling. DEA's alphabetical list of controlled substances places phentermine in Schedule IV, listing brand names including Adipex-P. Semaglutide, tirzepatide, liraglutide, naltrexone/bupropion (Contrave), and orlistat do not appear on it.
| Medication | DEA schedule | Telemedicine without in-person visit after 2026? |
|---|---|---|
| Phentermine (Adipex-P, Lomaira) | Schedule IV | Depends on DEA action before Dec 31, 2026 |
| Qsymia (phentermine/topiramate) | Schedule IV | Depends on DEA action before Dec 31, 2026 |
| Contrave (naltrexone/bupropion) | Not controlled | Not affected by DEA telemedicine rules |
| Semaglutide, tirzepatide, liraglutide | Not controlled | Not affected by DEA telemedicine rules |
| Orlistat | Not controlled | Not affected by DEA telemedicine rules |
Source: DEA Diversion Control Division controlled substances list; Qsymia prescribing information (rev. 03/2026).
Non-controlled drugs still need a valid prescription and must follow state telehealth and practice rules. They just aren't subject to the federal Ryan Haight Act restrictions discussed below.
The federal rule: Ryan Haight and the 2026 extension
The default
The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 limits online prescribing of controlled substances. As the December 31, 2025 Federal Register notice summarizes, a practitioner may prescribe remotely "only after conducting at least one in-person medical evaluation of that patient," subject to certain exceptions.
The temporary flexibilities
Since the COVID-19 public health emergency, DEA and HHS have repeatedly suspended that in-person requirement. The current notice, the "Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications," is effective January 1, 2026 through December 31, 2026. Under it, a DEA-registered practitioner may prescribe Schedule II through V medications to a patient never seen in person if:
- The prescription is for "a legitimate medical purpose by a practitioner acting in the usual course of professional practice."
- It results from a communication using an interactive telecommunications system as defined in Medicare's telehealth rules (42 CFR 410.78(a)(3)).
- The practitioner's DEA registration covers that class of drug.
- The prescription is consistent with DEA's other prescription requirements in 21 CFR part 1306.
DEA said the extension was meant to avoid a "telemedicine cliff" while it finished permanent rules.
The pending permanent rule
In January 2025, DEA proposed a special registration that would let qualifying practitioners prescribe controlled substances via telemedicine without a prior in-person visit; the Federal Register notice says DEA received over 6,475 comments. According to a September 18, 2026 McDermott Will & Schulte client alert, DEA submitted a final special registration rule to the Office of Information and Regulatory Affairs on August 25, 2026, which may be finalized before the flexibilities expire. The final text has not been published, so nobody outside the government knows its exact requirements yet.
Compare licensed providers →
See which licensed prescribers evaluate patients for weight-management medications, including non-controlled GLP-1 options; only a prescriber can decide what's appropriate, so confirm pricing and terms directly.
Paid links. We may earn a commission; it never changes what we write. See all options. Compounded medications are not FDA-approved.
Affiliate disclosure: this site may earn a commission if you use links in boxes like the one above. It does not affect what this guide says.
What could happen on January 1, 2027
There are three realistic scenarios. None is confirmed as of October 19, 2026.
| Scenario | What it would mean for a phentermine patient treated only online |
|---|---|
| Special registration final rule takes effect | Telemedicine prescribing continues for practitioners who meet the new rule's requirements, which are not yet public |
| Another temporary extension | Current flexibilities continue for the extension period |
| Flexibilities lapse with no replacement | Ryan Haight default applies: an in-person evaluation is needed before remote controlled-substance prescribing, subject to statutory exceptions |
Source: Federal Register 2025-24123 (Dec. 31, 2025); McDermott Will & Schulte (Sept. 18, 2026).
Practical steps before year-end
- Ask your prescriber about their plan. If your phentermine or Qsymia comes from a practitioner you've never met in person, ask how they will handle prescriptions after December 31, 2026.
- Know your refill limits. Under 21 CFR 1306.22, a Schedule III or IV prescription cannot be filled or refilled more than six months after issue or refilled more than five times. A prescription issued under the flexibilities doesn't let you stockpile.
- Consider an in-person visit. Under the Ryan Haight framework, an in-person evaluation by the prescribing practitioner is what allows later telemedicine prescribing of controlled drugs.
- Discuss non-controlled alternatives if relevant. If your treatment plan could shift to a non-controlled drug anyway, that conversation isn't affected by the deadline.
Phentermine's label: short-term by design
Separate from the telemedicine question, phentermine's own label limits how it is used. The Lomaira label on DailyMed describes phentermine as a short-term adjunct ("a few weeks") to diet, exercise, and behavior change for adults with a BMI of 30 or more, or 27 or more with risk factors such as controlled hypertension, diabetes, or high cholesterol. It states that "Phentermine is a Schedule IV controlled substance" and lists contraindications including cardiovascular disease, hyperthyroidism, glaucoma, agitated states, a history of drug abuse, pregnancy or nursing, and use within 14 days of an MAO inhibitor. It is not recommended for patients 16 or younger.
Qsymia is labeled for chronic weight management, not short-term use, and has extra controls. Its label says that under the Qsymia REMS, "only certified pharmacies may distribute QSYMIA," and it recommends a pregnancy test before starting and monthly during therapy for patients who can become pregnant. Adults who haven't lost at least 5% of body weight after 12 weeks on the top dose are told to taper off.
State rules: PDMP checks and continuation thresholds
Federal rules are the floor. States regulate how controlled substances are prescribed for weight loss, and prescribers must follow the rules of the state where the patient is located.
Prescription drug monitoring programs
The CDC describes a PDMP as "an electronic database that tracks controlled substance prescriptions." Phentermine fills are reported to these databases, and many states require prescribers to check them before prescribing controlled drugs. Expect your prescription history from other clinicians to be visible.
An example: Ohio's weight-loss controlled substance rule
Ohio's rule 4731-11-04 (effective February 28, 2023) shows how specific state rules get. Before starting a Schedule III or IV weight-loss drug, a prescriber must take a history, perform an appropriate examination, and review the patient's prior 12 months of prescriptions in Ohio's PDMP (OARRS). The rule bars starting treatment below a BMI of 30, or 27 with comorbidities, and stops further prescribing if the patient hasn't lost at least 5% of initial weight in the first three months. Other states have their own versions, so a telehealth service licensed in several states may apply different rules depending on where you live.
How to spot a prescriber that cuts corners
Because phentermine is a controlled drug, legitimate prescribing follows a recognizable pattern. Be cautious if a service offers a controlled-substance prescription after a form-only intake with no live visit, can't tell you which state license and DEA registration the prescriber holds, or promises refills beyond the six-month and five-refill limits in federal rules. Those are signs the prescription may not satisfy either the temporary flexibilities or your state's rules, which can leave you without a refill when a pharmacy or PDMP check flags it.
Checklist if you're prescribed phentermine online
- Confirm the prescriber is licensed in your state and holds a DEA registration for Schedule IV drugs.
- Expect a live video visit, not just a questionnaire, for a controlled-substance prescription.
- Have your blood pressure, heart rate, and weight ready; state rules commonly require them.
- Disclose every medication, including antidepressants and MAO inhibitors.
- Ask what happens to your prescriptions after December 31, 2026.
Check eligibility with a licensed provider →
A licensed prescriber can review your history and explain which options fit, controlled or not; confirm pricing and terms directly before you pay.
Paid links. We may earn a commission; it never changes what we write. See all options. Compounded medications are not FDA-approved.
Affiliate disclosure: this site may earn a commission if you use links in boxes like the one above. It does not affect what this guide says.
Frequently asked questions
Can I get phentermine prescribed through telehealth?
Through December 31, 2026, a DEA-registered prescriber may prescribe Schedule IV drugs like phentermine via real-time telemedicine without a prior in-person visit, under the fourth temporary DEA/HHS extension. State rules also apply.
What happens after December 31, 2026?
It depends on DEA. A final special registration rule was sent for White House review on August 25, 2026; if neither it nor another extension takes effect, the Ryan Haight Act default requiring an in-person evaluation returns.
Does the DEA deadline affect Wegovy, Zepbound, or other GLP-1s?
No. Semaglutide, tirzepatide, and liraglutide are not on DEA's controlled substance list, so the controlled-substance telemedicine rules don't apply to them.
Is Qsymia a controlled substance?
Yes. Qsymia is Schedule IV because of its phentermine component, and it is dispensed only through certified pharmacies under a REMS program.
How long can phentermine be prescribed?
Phentermine-only products are labeled as a short-term adjunct of a few weeks. Some states, such as Ohio, also stop further prescribing if a patient hasn't lost at least 5% of initial weight in the first three months.
Sources
- Federal Register 2025-24123: Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications (Dec. 31, 2025)
- McDermott Will & Schulte: DEA appears close to finalizing telemedicine special registration (Sept. 18, 2026)
- DEA Diversion Control Division: Controlled Substances, alphabetical order
- Lomaira (phentermine hydrochloride) tablets label, DailyMed
- Qsymia (phentermine and topiramate) prescribing information, FDA (rev. 03/2026)
- 21 CFR 1306.22: Refilling of prescriptions (Schedules III and IV)
- CDC: Prescription Drug Monitoring Programs
- Ohio Admin. Code 4731-11-04: Controlled substances for weight reduction
Medical disclaimer: This article is general information, not medical advice, and does not replace a licensed clinician who knows your history. Approvals, labels, coverage and prices change; check the linked sources and talk with your prescriber or pharmacist before making decisions about any medication.